TORONTO, ON / ACCESSWIRE / May 15, 2015 / The Canadian Bioceutical Corporation (TSX VENTURE:BCC) ("BCC " or the "Company") reports a change of auditor. McGovern, Hurley, Cunningham, LLP has resigned by mutual agreement effective [XX] and the directors of the Company have appointed Collins Barrow Toronto LLP as successor auditor of the Company effective May 14, 2015 until the close of the Company's next annual general meeting. The change in auditor has been approved by the Company's audit committee and board of directors.
There were no reservations in McGovern, Hurley, Cunningham, LLP’s reports in connection with the most recently completed fiscal year (2014) or for any period subsequent to the most recently completed period for which an audit report was issued preceding the date of McGovern, Hurley, Cunningham, LLP’s resignation. To the Company's knowledge, there were also no "reportable events" (as that term is defined in National Instrument 51-102 Continuous Disclosure Obligations) between the Company and McGovern, Hurley, Cunningham, LLP.
In accordance with National Instrument 51-102, the notice of change of auditor, together with the required letters from the former auditor and the successor auditor, have been reviewed by the audit committee and the board of directors and will be filed on SEDAR accordingly.
About The Canadian Bioceutical Corporation
BCC, formerly Allegiance Equity Corporation, is an Ontario corporation that, for over two decades has been developing unique standardized mass-market nutraceutical products for the treatment of common ailments where present pharmaceutical treatments and over-the-counter products fail to meet the needs of patients. BCC has targeted markets having clearly identified product deficiencies and dissatisfied consumers afflicted with a variety of medical conditions. BCC obtains regulatory approval and patents for these unique compounds and formulations and may produce and distribute or license its products for royalty revenues.
BCC's principal brands are CinG-X(TM), ReliévaTM, and Psorberine(TM) and FertaMaxTM. Additionally BCC, through its wholly-owned subsidiary BioCannabis Products Ltd. and, subsequent to receiving its MMPR license from Health Canada and the potential revision of the related regulations, intends to develop and market a series of new cannabis-based branded medicinal products to address this rapidly-evolving market.
Additional details in relation to BCC's plan to enter into the medical marijuana sector may be found in the company's two News Releases of January 7, 2015.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the Policies of the Exchange) accepts responsibility of the adequacy or accuracy of this release.
For further information please contact:
Scott Boyes, President and CEO
scott@canadianbioceutical.com
(416) 840-4703
SOURCE: The Canadian Bioceutical Corporation
